Literature DB >> 26138634

Blood-brain barrier-associated efflux transporters: a significant but underappreciated obstacle to drug development in glioblastoma.

Warren P Mason1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26138634      PMCID： PMC4588763          DOI： 10.1093/neuonc/nov122

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  14 in total

1.  A phase I study of temozolomide and everolimus (RAD001) in patients with newly diagnosed and progressive glioblastoma either receiving or not receiving enzyme-inducing anticonvulsants: an NCIC CTG study.

Authors:  Warren P Mason; Mary Macneil; Petr Kavan; Jacob Easaw; David Macdonald; Brian Thiessen; Shweta Urva; Zarnie Lwin; Lynn McIntosh; Elizabeth Eisenhauer
Journal:  Invest New Drugs       Date:  2011-12-09       Impact factor: 3.850

2.  Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study.

Authors:  Evanthia Galanis; Jan C Buckner; Matthew J Maurer; Jeffrey I Kreisberg; Karla Ballman; J Boni; Josep M Peralba; Robert B Jenkins; Shaker R Dakhil; Roscoe F Morton; Kurt A Jaeckle; Bernd W Scheithauer; Janet Dancey; Manuel Hidalgo; Daniel J Walsh
Journal:  J Clin Oncol       Date:  2005-07-05       Impact factor: 44.544

Review 3.  Breast cancer resistance protein and P-glycoprotein in brain cancer: two gatekeepers team up.

Authors:  Sagar Agarwal; Anika M S Hartz; William F Elmquist; Björn Bauer
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

4.  Active efflux of Dasatinib from the brain limits efficacy against murine glioblastoma: broad implications for the clinical use of molecularly targeted agents.

Authors:  Sagar Agarwal; Rajendar K Mittapalli; David M Zellmer; Jose L Gallardo; Randy Donelson; Charlie Seiler; Stacy A Decker; Karen S Santacruz; Jenny L Pokorny; Jann N Sarkaria; William F Elmquist; John R Ohlfest
Journal:  Mol Cancer Ther       Date:  2012-08-13       Impact factor: 6.261

5.  Function of the blood-brain barrier and restriction of drug delivery to invasive glioma cells: findings in an orthotopic rat xenograft model of glioma.

Authors:  Sagar Agarwal; Pooja Manchanda; Michael A Vogelbaum; John R Ohlfest; William F Elmquist
Journal:  Drug Metab Dispos       Date:  2012-09-26       Impact factor: 3.922

Review 6.  Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy.

Authors:  Rakesh K Jain
Journal:  Science       Date:  2005-01-07       Impact factor: 47.728

Review 7.  The blood-brain barrier and cancer: transporters, treatment, and Trojan horses.

Authors:  John F Deeken; Wolfgang Löscher
Journal:  Clin Cancer Res       Date:  2007-03-15       Impact factor: 12.531

8.  Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme.

Authors:  Ulrik Lassen; Morten Sorensen; Tine Bernhardtsen Gaziel; Benedikte Hasselbalch; Hans Skovgaard Poulsen
Journal:  Anticancer Res       Date:  2013-04       Impact factor: 2.480

9.  Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization.

Authors:  An Claes; Pieter Wesseling; Judith Jeuken; Cathy Maass; Arend Heerschap; William P J Leenders
Journal:  Mol Cancer Ther       Date:  2008-01-09       Impact factor: 6.261

10.  Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma.

Authors:  Tim F Cloughesy; Koji Yoshimoto; Phioanh Nghiemphu; Kevin Brown; Julie Dang; Shaojun Zhu; Teli Hsueh; Yinan Chen; Wei Wang; David Youngkin; Linda Liau; Neil Martin; Don Becker; Marvin Bergsneider; Albert Lai; Richard Green; Tom Oglesby; Michael Koleto; Jeff Trent; Steve Horvath; Paul S Mischel; Ingo K Mellinghoff; Charles L Sawyers
Journal:  PLoS Med       Date:  2008-01-22       Impact factor: 11.069
View more
  7 in total

1.  Combined CDK4/6 and mTOR Inhibition Is Synergistic against Glioblastoma via Multiple Mechanisms.

Authors:  Inan Olmez; Breanna Brenneman; Aizhen Xiao; Vlad Serbulea; Mouadh Benamar; Ying Zhang; Laryssa Manigat; Tarek Abbas; Jeongwu Lee; Ichiro Nakano; Jakub Godlewski; Agnieszka Bronisz; Roger Abounader; Norbert Leitinger; Benjamin Purow
Journal:  Clin Cancer Res       Date:  2017-08-16       Impact factor: 12.531

2.  Anorexic response to rapamycin does not appear to involve a central mechanism.

Authors:  Hale Z Toklu; Erin B Bruce; Yasemin Sakarya; Christy S Carter; Drake Morgan; Michael K Matheny; Nataliya Kirichenko; Philip J Scarpace; Nihal Tümer
Journal:  Clin Exp Pharmacol Physiol       Date:  2016-09       Impact factor: 2.557

Review 3.  The role of extracellular vesicles in acquisition of resistance to therapy in glioblastomas.

Authors:  Anudeep Yekula; Abigail Taylor; Alexandra Beecroft; Keiko M Kang; Julia L Small; Koushik Muralidharan; Zachary Rosh; Bob S Carter; Leonora Balaj
Journal:  Cancer Drug Resist       Date:  2021-03-19

4.  Passage of Magnetic Tat-Conjugated Fe3O4@SiO2 Nanoparticles Across In Vitro Blood-Brain Barrier.

Authors:  Xueqin Zhao; Ting Shang; Xiaodan Zhang; Ting Ye; Dajin Wang; Lei Rei
Journal:  Nanoscale Res Lett       Date:  2016-10-10       Impact factor: 4.703

Review 5.  Drug Repurposing, a Fast-Track Approach to Develop Effective Treatments for Glioblastoma.

Authors:  Ioannis Ntafoulis; Stijn L W Koolen; Sieger Leenstra; Martine L M Lamfers
Journal:  Cancers (Basel)       Date:  2022-07-29       Impact factor: 6.575

6.  SerpinB3 drives cancer stem cell survival in glioblastoma.

Authors:  Adam Lauko; Josephine Volovetz; Soumya M Turaga; Defne Bayik; Daniel J Silver; Kelly Mitchell; Erin E Mulkearns-Hubert; Dionysios C Watson; Kiran Desai; Manav Midha; Jing Hao; Kathleen McCortney; Alicia Steffens; Ulhas Naik; Manmeet S Ahluwalia; Shideng Bao; Craig Horbinski; Jennifer S Yu; Justin D Lathia
Journal:  Cell Rep       Date:  2022-09-13       Impact factor: 9.995

Review 7.  Challenges and Opportunities of Deferoxamine Delivery for Treatment of Alzheimer's Disease, Parkinson's Disease, and Intracerebral Hemorrhage.

Authors:  Amy Corbin Farr; May P Xiong
Journal:  Mol Pharm       Date:  2020-10-09       Impact factor: 4.939
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.